Clinical Trials
55 trialsTAILORx
National Cancer Institute (NCI)
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Novartis
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
NAOMI
Dartmouth-Hitchcock Medical Center
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
FourLight-3
Pfizer
GIM10-CONSENT
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
SERENA-6
AstraZeneca
PIKASSO-01
Eli Lilly and Company
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Providence Health & Services
ADEPT
Dana-Farber Cancer Institute
EMBER-4
Eli Lilly and Company
CARABELA
Spanish Breast Cancer Research Group
FELINE
University of Kansas Medical Center
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
PATINA
Alliance Foundation Trials, LLC.
e3
SWOG Cancer Research Network
VERITAC-3
Pfizer
MONARCH plus
Eli Lilly and Company
MONARCH 3
Eli Lilly and Company
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
OVELIA
Tolmar Inc.
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
University of Kentucky
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
POWER
University of Virginia
CDK4i
Pfizer
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
National University Hospital, Singapore
AMBRE
UNICANCER
NEOLBC
Borstkanker Onderzoek Groep
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
BeiGene
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Dana-Farber Cancer Institute
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HARMONIA
SOLTI Breast Cancer Research Group
PHERGain
MedSIR
HELEX
Baylor Breast Care Center
FACILE
Fondazione Sandro Pitigliani
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
Seoul National University Hospital
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
GIM4
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy